Human Health Platform
SCYNEXIS is committed to working on the discovery of novel parasiticides for the Neglected Tropical Diseases. Over the last six years SCYNEXIS has partnered with Public Private Partnership’s (PPP’s) for the discovery and optimization of compounds for neglected disease indications. SCYNEXIS has developed a state-of-the-art platform for the assessment of compounds against a broad spectrum of parasites relevant to these key parasiticide targets.
SCYNEXIS Case Study– African Sleeping Sickness
In 2006, SCYNEXIS partnered with Drugs for Neglected Diseases initiative (DNDi) through the Bill and Melinda Gates Foundation to find effective and less toxic treatments for Human African Trypanosomiasis (HAT) or sleeping sickness. SCYNEXIS led the discovery collaboration that resulted in the identification of SCYX-7158, the first potential new treatment for Stage 1 and Stage 2 HAT in over 40 years. SCYNEXIS biologists screened multiple chemical libraries directly against trypanosome parasites to identify starting points for chemical optimization. SCYNEXIS chemists and DMPK scientists worked with the biologists to form an integrated team to optimize lead chemical series to meet the Target Product Profile defined by DNDi and their clinical development partners. SCYX-7158 was identified as the lead candidate and selected as a pre-clinical development candidate 18 months after the start of the lead optimization process. The pre-clinical phase was completed in 20 months and SCYX-7158 is currently in Phase I clinical trials.
We would be happy to discuss our technical expertise and business model with you in more detail to determine opportunities to work with your organization.